The results of NOR-SWITCH, the Norwegian government-sponsored study on switching patients from Johnson & Johnson’s Remicade (infliximab) to Celltrion’s biosimilar version Remsima (CT-P13), have generated a great deal of controversy since they were published last month, especially over how far the data support the safety of switching.
Now J&J subsidiary Janssen Biotech Inc., which has been advocating clinical testing of biosimilars across the different indications of...






